Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

Phase 2

AbbVie (prior sponsor, Abbott)

Cholinesterase Inhibitors